Humacyte, Inc. Common Stock
Market Cap
310M
Short interest (May 15)
18.5%
Net Short (Jun 03 ): -0.1%
Borrow Fee
17.05%
↓ 14.2%
Available Shares
300K
↓ 18.5%
Price Chart
Company Overview
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.